A prospective, multicentric, phase 2 clinical trial was conducted to test a combination treatment with encorafenib (BRAFinhibitor) and binimetinib (MEK inhibitor) followed by radiotherapy in patients with BRAF V600-positive melanoma and brain metastases. Here, MAP2K7 is linked to melanoma.